Crenezumab Biosimilar - Anti-beta Amyloid Antibody - Low endotoxin, Azide free (A323372)

Crenezumab Biosimilar - Anti-beta Amyloid Antibody - Low endotoxin, Azide free

Recombinant humanized monoclonal antibody to beta Amyloid.

ELISA, FACS, Functional Assay, In Vivo

Human, Mouse, Cynomolgus Macaque

Humanized

Monoclonal

IgG4SP - Human IgG4 with S228P mutation

kappa

Unconjugated

Protein A affinity chromatography.

Reconstitution dependent.

> 95% (by SDS-PAGE and SEC-HPLC).

Lyophilized

Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml concentration. Gently shake to solubilize completely. Do not vortex!

Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.

Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.

A4_HUMAN, AAA, ABETA, ABPP, AD1, AICD-50, AICD-57, AICD-59, AID(50), AID(57), AID(59), Alzheimer disease amyloid protein, amyloid beta A4 protein, Amyloid intracellular domain 50, Amyloid intracellular domain 57, Amyloid intracellular domain 59, amyloid of aging and alzheimer disease, APP, APPI, beta-amyloid peptide, Beta-APP40, Beta-APP42, C31, Cerebral vascular amyloid peptide, CTFgamma, CVAP, Gamma-CTF(50), Gamma-CTF(57), Gamma-CTF(59), peptidase nexin-II, PN-II, PreA4, Protease nexin-II, S-APP-alpha, S-APP-beta